Genetic hypoparathyroidism

Genetic hypoparathyroidism refers to a group of inherited disorders characterized by deficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands, leading to low blood calcium levels (hypocalcemia) and elevated blood phosphate levels (hyperphosphatemia). Unlike acquired forms of hypoparathyroidism (such as those resulting from surgical removal of the parathyroid glands), genetic hypoparathyroidism arises from mutations in genes involved in parathyroid gland development, PTH synthesis, or calcium-sensing regulation. Causative genes include GCM2, PTH, CASR (activating mutations), and GNA11, among others. The condition may present as an isolated finding (isolated familial hypoparathyroidism) or as part of broader syndromes such as DiGeorge syndrome, HDR syndrome (hypoparathyroidism, deafness, renal dysplasia), or autoimmune polyendocrinopathy. The primary body systems affected include the musculoskeletal, neurological, and cardiovascular systems. Key symptoms result from hypocalcemia and include muscle cramps, tingling or numbness in the fingers, toes, and around the mouth (perioral paresthesias), muscle spasms (tetany), seizures, and in severe cases, laryngospasm or cardiac arrhythmias. Chronic hypocalcemia can lead to cataracts, dental abnormalities, basal ganglia calcifications, and impaired cognitive function. In children, the condition may present with failure to thrive, developmental delay, or neonatal seizures depending on the severity and underlying genetic cause. Treatment of genetic hypoparathyroidism focuses on correcting and maintaining normal calcium and phosphate levels. Standard therapy includes oral calcium supplements and active vitamin D analogs (such as calcitriol or alfacalcidol). Recombinant parathyroid hormone (rhPTH 1-84) has been approved as replacement therapy for adults with hypoparathyroidism inadequately controlled on conventional treatment. Regular monitoring of serum calcium, phosphate, renal function, and urinary calcium excretion is essential to avoid complications such as nephrocalcinosis and kidney stones. Genetic counseling is recommended for affected families to clarify the specific inheritance pattern and recurrence risk.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic hypoparathyroidism